<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03900143</url>
  </required_header>
  <id_info>
    <org_study_id>DO114314A</org_study_id>
    <nct_id>NCT03900143</nct_id>
  </id_info>
  <brief_title>Safety, Efficacy and Usage Compliance of the Silk'n Tightra Device</brief_title>
  <official_title>Safety, Efficacy and Usage Compliance of the Silk'n Tightra Home Use Device for Improvement of Sexual Functioning, Vulvovaginal Appearance and Reduction of SUI.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Home Skinovations Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Home Skinovations Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, prospective study aimed to evaluate safety and efficacy of the Silk'n&#xD;
      Tightra device for improvement of sexual functioning, vulvovaginal appearance and reduction&#xD;
      of SUI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, prospective study aimed to evaluate safety and efficacy of the Silk'n&#xD;
      Tightra device.&#xD;
&#xD;
      The study includes 12 treatment sessions 3 times a week, over a period of 4 weeks. Each&#xD;
      subject will serve as her own control, while comparing results before and after treatment.&#xD;
      Treatment will be performed on the internal volva for 20 min according to the device&#xD;
      instructions, .&#xD;
&#xD;
      Subjects that are interested in improving their labial appearance, and are willing to perform&#xD;
      the external treatment twice a week in addition to the internal treatments, will be offered&#xD;
      to conduct both treatments. The study will include one follow-up visit conducted one month&#xD;
      following treatment end. During the second month of the study subjects will perform&#xD;
      mainte-nance treatments and will gradually reduce the frequency of the treat-ments as&#xD;
      follows:&#xD;
&#xD;
        -  Week 5: 2 treatments&#xD;
&#xD;
        -  Weeks 6-8: 1 treatment per week.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 28, 2019</start_date>
  <completion_date type="Actual">March 25, 2019</completion_date>
  <primary_completion_date type="Actual">March 25, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>An improvement in stress urinary incontinence</measure>
    <time_frame>8 weeks</time_frame>
    <description>Improvement in SUI according to a validated questionnaire (ICIQ)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>An improvement in stress urinary incontinence</measure>
    <time_frame>8 weeks</time_frame>
    <description>Improvement in SUI according to a validated questionnaire (IIQ-7)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>improvement in sexual functioning</measure>
    <time_frame>8 weeks</time_frame>
    <description>according to a validated questionnaire (FSFI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in vaginal tightening (reduced laxity) and improvement in volvovaginal symptoms</measure>
    <time_frame>8 weeks</time_frame>
    <description>According to a validated questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in general satisfaction from the devcie</measure>
    <time_frame>8 weeks</time_frame>
    <description>According to a satisfaction questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level of reduction in sexual distress</measure>
    <time_frame>8 weeks</time_frame>
    <description>According to a validated questionnaire (FSDS)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Stress Urinary Incontinence</condition>
  <condition>Sexual Dysfunction</condition>
  <condition>Vulvovaginal Atrophy</condition>
  <arm_group>
    <arm_group_label>Treatment - Tightra</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment group with the Tightra device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tightra vaginal device</intervention_name>
    <description>Vaginal device for improvement of vaginal symptoms, reduce vaginal laxity, improve sexual functioning, and treat stress urinary incontinence.</description>
    <arm_group_label>Treatment - Tightra</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 25-65 (at least 18 women in the range of 40-65 and approxi-mately 10 women in the&#xD;
             range of 25 - 40)&#xD;
&#xD;
          2. The subject has symptoms of vaginal relaxation syndrome and uri-nary incontinence, and&#xD;
             desires vaginal rejuvenation treatment.&#xD;
&#xD;
          3. The subject has had at least one vaginal delivery&#xD;
&#xD;
          4. The subject is sexually active.&#xD;
&#xD;
          5. The subject suffers from bad sexual functioning due to vaginal laxity and/or other&#xD;
             vaginal symptoms.&#xD;
&#xD;
          6. Negative PAP smear and pelvic exam done within last 2 years.&#xD;
&#xD;
          7. The subjects should understand the information provided about the investigative nature&#xD;
             of the treatment, possible benefits and side ef-fects, and sign the Informed Consent&#xD;
             Form.&#xD;
&#xD;
          8. The subjects should be willing to comply with the study procedure and schedule,&#xD;
             including the follow up visits.&#xD;
&#xD;
          9. The subject is able to read the User Manual.&#xD;
&#xD;
         10. Negative results in a urine pregnancy test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active electrical implant/device in any region of the body - Pacemak-er or internal&#xD;
             defibrillator.&#xD;
&#xD;
          2. Presence of vulvar lesions or disease (dermatitis, human papilloma-virus, herpes&#xD;
             simplex, vulvar dystrophy, etc.).&#xD;
&#xD;
          3. Superficial metal, piercing or other implants in the treatment area.&#xD;
&#xD;
          4. Vaginal or pelvic surgery or anti-incontinence surgery within the past 12 months.&#xD;
&#xD;
          5. Current urinary tract infection, pelvic or pelvic tract infection&#xD;
&#xD;
          6. Current cancer condition or pre-malignant moles.&#xD;
&#xD;
          7. History of skin and genital areas cancer.&#xD;
&#xD;
          8. Severe concurrent conditions, such as cardiac disorders, sensory dis-turbances,&#xD;
             epilepsy, uncontrolled hypertension, and liver or kidney diseases, per investigator's&#xD;
             discretion.&#xD;
&#xD;
          9. Pregnancy, nursing, or planned pregnancy within the next two months.&#xD;
&#xD;
         10. Prior labiaplasty&#xD;
&#xD;
         11. presence of major psychiatric conditions or related need for medica-tion&#xD;
&#xD;
         12. Diffuse pain syndrome or chronic pain requiring daily narcotics&#xD;
&#xD;
         13. Chronic use of anti-inflammatory agents (including steroids) and im-munosuppressants.&#xD;
&#xD;
         14. Undiagnosed abnormal genital bleeding&#xD;
&#xD;
         15. Presence of any condition or use of medication known to interfere with sexual activity&#xD;
&#xD;
         16. Poorly controlled endocrine disorders, such as Diabetes, or thyroid dysfunction and&#xD;
             hormonal virilisation.&#xD;
&#xD;
         17. Isotretinoin (Accutane) within last 6 months.&#xD;
&#xD;
         18. Uterine prolapse, cystocele or rectocele.&#xD;
&#xD;
         19. History of bleeding coagulopathies, or use of anticoagulants except for low-dose&#xD;
             aspirin.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>only women should participate in this study</gender_description>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marianne Brandt, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>proDERM research institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ProDERM</name>
      <address>
        <city>Hamburg</city>
        <zip>22869</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 25, 2019</study_first_submitted>
  <study_first_submitted_qc>April 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2019</study_first_posted>
  <last_update_submitted>May 6, 2019</last_update_submitted>
  <last_update_submitted_qc>May 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

